- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05650762
Controlling Malodour In Fungating Wounds Using A Cinnamon-Based Dressing: Observational Study
The purpose of the study is to observe the contribution of the cinnamon dressing to the reduction of the discomfort associated with the odour felt by the patient and carers.
This prospective study aims to collect data on patients living with a malodorous fungating wound. Quality of life tools will be used to assess the impact of the cinnamon dressing on managing malodorous fungating wounds.
Study Overview
Detailed Description
There are several anti-odour treatments on the market for managing malodorous wounds but no conclusive data on their efficacy is available. Current treatments like charcoal dressing or topical antimicrobials do not completely manage bad odours in particular for tumoral wounds. In the case of malodorous wounds, the ideal management plan would therefore be to reduce (or neutralise) bad odours, and modify any residual odour so that it becomes more pleasant than unpleasant.
Cinesteam® was specially developed to reduce and manage malodorous wounds. Cinesteam® is a secondary dressing that eliminates unpleasant odours and masks any residual odours with the spice's natural fragrance. This dressing also absorbs excess exudates released by the wound.
The aim of this post-market observational study is to observe the performance of Cinesteam® in controlling malodour in fungating wounds. Patients with malodourous, fungating wounds, above 18 years with a discomfort score of >40/100, with cognitive ability to participate and consent, will be eligible to participate in the study. The study will be conducted on eligible patients in the North East of England, treated at the Newcastle upon Tyne Hospitals NHS Foundation Trust, either as inpatients or in its surrounding community.
The duration of patient participation in the study is 14 days. The research nurse will visit patients on Day0 and perform wound assessment, apply Cinesteam dressing over the standard care primary dressing and answer questionnaires on odour, and discomfort, and also help patients with questionnaires on odour, discomfort, appetite and Quality of life.
The research nurse will change Cinesteam dressing on Day 1, Day 7 +/- 48 hours, and Day 14 +/- 48 hours and perform follow-up assessments on patients' wound condition. Patients or their caregivers who usually change the patient's dressing will change the primary dressing and Cinesteam dressing in-between the research nurse's assessment visits. They will keep a record of these dressing changes in the diary provided.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Newcastle Upon Tyne, United Kingdom, NE7 7DN
- The Newcastle Upon Tyne Hospital NHS Foundation Trust
-
Principal Investigator:
- Fania Pagnamenta, Dr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient > 18 years old with malodorous fungating wounds
- Discomfort > 40/100 expressed by the patient);
- Patients who have capacity to consent;
- Patients who are cognitively able and willing to participate;
- Patients who have a good command of the English language.
Exclusion Criteria:
- Patient with pressure ulcers, leg ulcers, diabetic feet ulcers;
- Terminally ill patients whose life expectancy is less than the duration of the protocol;
- Patients having had metronidazole treatment for fewer than 3 days before enrolment in the study;
- Patients who are unable or willing to participate;
- Anosmic patient (with no sense of smell);
- Patient with cinnamon allergy;
- Persons deprived of their liberty or under guardianship;
- Unable to take part in study procedures for whatever reason;
- Pregnant or lactating women.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Cinnamon
|
Cinnamon-based Secondary dressing
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change from baseline patient wound odour at different timepoints using a Visual Analogue Scale (VAS-100mm scale), from 0 (no smell) to 100 (worst smell imaginable)
Time Frame: Baseline visit, one day, 7 and 14 days after baseline visit
|
Baseline visit, one day, 7 and 14 days after baseline visit
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change from baseline patient discomfort associated with the wound odour at different timepoints using a Visual Analogue Scale (VAS-100mm scale), from 0 (no discomfort) to 100 (Unbearable discomfort during the sleeping and waking hours)
Time Frame: Baseline visit, one day, 7 and 14 days after baseline visit
|
Baseline visit, one day, 7 and 14 days after baseline visit
|
|
Change from baseline patient quality of life at different timepoints using the questionnaire of EuroQol 5 Dimension 5 Level (EQ-5D-5L)
Time Frame: Baseline visit, one day and 14 days after baseline visit
|
Baseline visit, one day and 14 days after baseline visit
|
|
Change from baseline investigator-rating the strength of the wound odour and smell at different timepoints using TELERTM from none odour to very strong odour.
Time Frame: Baseline visit, one day, 7 and 14 days after baseline visit
|
Baseline visit, one day, 7 and 14 days after baseline visit
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CIN-S22001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Wound
-
Brigham and Women's HospitalCompletedSurgical Wound | Wound Heal | Wound of Skin | Wound OpenUnited States
-
ConvaTec Inc.WithdrawnSurgical Wound, Recent | Trauma-related Wound | Dehiscence Wound | Surgical Wound LeakUnited States
-
Chandan SenUniversity of Colorado, DenverRecruitingInfections | Wound Infection | Wound Heal | Wound of Skin | Wound Healing DelayedUkraine
-
Massachusetts General HospitalCompletedWound Healing | Traumatic Wound | Infective Wound | Iatrogenic Critical Sized Wound DefectsUnited States
-
Indus Hospital and Health NetworkCompletedWound Closure After Total Knee Arthroplasty: Comparison of Polypropylene and Polyglactin 910 Suture.Wound Heal | Wound Complication | Wound DehiscencePakistan
-
Pulmatrix Inc.TerminatedPost Operative Wound Infection | Postoperative Wound Infection-deepUnited States
-
University of Roma La SapienzaCompletedWound Heal | Wound Surgical | Oral Soft Tissue ConditionsItaly
-
Brigham and Women's HospitalRecruitingWound Infection and Wound HealingUnited States
-
St. Borbala HospitalSemmelweis University; Department of Surgery, Jahn Ferend Dél-Pesti Kórház... and other collaboratorsTerminatedSurgical Wound | Surgical Site Infection | Wound Dehiscence, Surgical | Dehiscence of Internal Surgical WoundHungary
-
Chulalongkorn UniversityUnknownWound Heal | Wound Surgical | Donor Site ComplicationThailand